IgG4-related disease and prostate cancer: A case report and review of the literature

Adam Zekhnini; Daniel Taussky; Jean-Baptiste Lattouf; Martial Koenig

doi:10.1016/j.eucr.2023.102538

IgG4-related disease and prostate cancer: A case report and review of the literature

Urol Case Rep. 2023 Aug 19:50:102538. doi: 10.1016/j.eucr.2023.102538. eCollection 2023 Sep.

Authors

Adam Zekhnini¹, Daniel Taussky¹, Jean-Baptiste Lattouf², Martial Koenig³

Affiliations

¹ Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal, Montréal, Canada.
² Division of Urology, Department of Surgery, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.
³ Internal Medicine Service, Centre hospitalier Universitaire de Montréal (CHUM), Montréal, Québec, Canada.

Abstract

We present a case of a patient with recurrent prostate cancer after treatment for favorable intermediate risk cancer. There was an exceptionally steep increase in PSA from <0.5 to 130ng/mL in 27 months accompanied with the development of bone metastasis. The PSA increase was unexpected. We suspect that this unusual development of metastases must have been caused by an impairment of the immune system caused by his IgG4 disease, and this may have allowed residual prostate cancer cells in the prostate to spread quickly. The influence of IgG4 on cancer is debated.

Keywords: IgG4; Prostate cancer; Rituximab.

Publication types

Case Reports